2019
DOI: 10.1136/bmjgh-2019-edc.26
|View full text |Cite
|
Sign up to set email alerts
|

Oc 8510 biotransformation of Praziquantel for the Pharmacokinetic Optimisation of Praziquantel Use in Mass Drug Administration and Development of New Paediatric Formulations

Abstract: BackgroundPraziquantel (PZQ) is the only drug available for the treatment of all forms of schistosomiasis. New paediatric formulations for the active enantiomer R-PZQ and the racemate PZQ are currently under development. There is however limited drug metabolism and pharmacokinetic data on PZQ available to support these initiatives. Detailed knowledge of PZQ metabolism will enable the use of PBPK modelling to determine appropriate doses for the new formulations in paediatric patients and to predict risks for dr… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Year Published

2022
2022
2022
2022

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
references
References 0 publications
0
0
0
Order By: Relevance